CLAIMS

1. Compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, for use in the treatment of metastatic or advanced breast cancer at a dose of 150 to 600 mg per day.

2. The compound for use according to claim 1, wherein said dose is 400 to 600 mg per day.

3. The compound for use according to claim 1 or claim 2, wherein said dose is 400 mg per day.

4. The compound for use according to any of claims 1 to 3, wherein said use is for a human patient.

5. The compound for use according to any of claims 1 to 4, wherein the breast cancer is an estrogen receptor positive cancer.

6. The compound for use according to any of claims 1 to 5, wherein the breast cancer is a human epidermal growth factor receptor 2 negative cancer.

7. The compound for use according to any of claims 1 to 6, wherein the breast cancer is an estrogen receptor positive, human epidermal growth factor receptor 2 negative cancer.

8. The compound for use according to any of claims 1 to 7, wherein the cancer is metastatic.

9. The compound for use according to any of claims 1 to 8, wherein the patient has been pretreated with at least one endocrine therapy treatment for advanced cancer.

10. The compound for use according to claim 9, wherein the patient demonstrates disease progression or recurrence after said endocrine therapy.

11. The compound for use according to claim 9 or 10, wherein the patient has been pretreated with at least one chemotherapy and/or targeted therapy such as a tyrosine kinase

inhibitor.

12. The compound for use according to claim 9 or 10, wherein the patient has been pretreated with one to three chemotherapies and/or one or more targeted therapies, with a range of 1 to 8 prior anti-cancer treatments.

13. The compound for use according to any of claims 1 to 12, wherein the patient has received no more than 3 prior lines of anti-cancer therapies, has received no prior mTOR inhibitor treatment, and has optionally received a prior chemotherapy or a CDK4/6 inhibitor treatment but not both.

14. The compound for use according to any of claims 1 to 12, wherein the patient has received neither prior targeted therapies, such as mTOR or CDK4/6 inhibitors, nor prior SERD therapy, such as fulvestrant.

15. The compound for use according to any of claims 1 to 14, wherein the patient is a woman.

16. The compound for use according to claim 15, wherein the patient is a postmenopausal woman.

17. The compound for use according to claim 15, wherein the patient is a premenopausal woman on menopause-inducing medication.

18. Use of a therapeutically effective amount of 150-600 mg per day of compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating metastatic or advanced breast cancer.

19. A pharmaceutical composition comprising 150 to 600 mg of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, as well as at least one pharmaceutically acceptable excipient.

20. Use of a pharmaceutical composition according to claim 19 in the manufacture of a medicament for treating metastatic or advanced breast cancer.

21. An article of manufacture, a packaging, or an administration unit, comprising:

- a packaging material;
- the pharmaceutical composition according to claim 19; and
- a label or package insert contained within said packaging material, indicating that said pharmaceutical composition is administered to a patient for the treatment of metastatic or advanced breast cancer, at a dose of 150 to 600 mg per day of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.